SanBio (4592) Stock Overview
Engages in the development, production, and sale of regenerative cell medicines for the central nervous system in Japan and the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
4592 Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
SanBio Company Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | JP¥948.00 |
| 52 Week High | JP¥3,990.00 |
| 52 Week Low | JP¥874.00 |
| Beta | 0.28 |
| 1 Month Change | -9.11% |
| 3 Month Change | -19.32% |
| 1 Year Change | -60.38% |
| 3 Year Change | 34.47% |
| 5 Year Change | -24.70% |
| Change since IPO | -46.53% |
Recent News & Updates
4592: NHI Listing For Traumatic Brain Injury Therapy Will Drive Future Upside
Analysts have revised their SanBio price target from ¥2,900 to ¥2,200, citing updated assumptions on revenue growth, profit margins and a much lower forward P/E multiple as key drivers of the change. What's in the News SanBio received National Health Insurance (NHI) listing in Japan for AKUUGO Suspension for Intracranial Implantation, with the final NHI price and reimbursement coverage now formally confirmed following publication in the Official Gazette.
4592: Conditional Approval And Reimbursement Will Support Future Regenerative Therapy Upside
Analysts have reduced their price target on SanBio from ¥2,100 to ¥1,660, citing updated assumptions around the discount rate, revenue growth, profit margin, and a higher future P/E multiple. What’s in the News for SanBio SanBio received marketing approval in Japan on July 31, 2024 for AKUUGO Suspension for Intracranial Implantation, indicated for improving chronic motor paralysis associated with traumatic brain injury.Recent updates
4592: NHI Listing For Traumatic Brain Injury Therapy Will Drive Future Upside
Analysts have revised their SanBio price target from ¥2,900 to ¥2,200, citing updated assumptions on revenue growth, profit margins and a much lower forward P/E multiple as key drivers of the change. What's in the News SanBio received National Health Insurance (NHI) listing in Japan for AKUUGO Suspension for Intracranial Implantation, with the final NHI price and reimbursement coverage now formally confirmed following publication in the Official Gazette.4592: Conditional Approval And Reimbursement Will Support Future Regenerative Therapy Upside
Analysts have reduced their price target on SanBio from ¥2,100 to ¥1,660, citing updated assumptions around the discount rate, revenue growth, profit margin, and a higher future P/E multiple. What’s in the News for SanBio SanBio received marketing approval in Japan on July 31, 2024 for AKUUGO Suspension for Intracranial Implantation, indicated for improving chronic motor paralysis associated with traumatic brain injury.Regenerative Medicine Tailwinds Will Support Long Term Brain Disease Treatment Potential
Catalysts About SanBio SanBio is a regenerative medicine company focused on cell therapies for brain diseases such as traumatic brain injury. What are the underlying business or industry changes driving this perspective?Brain Regeneration Platform Will Transform Chronic Injury Treatment And Open Multiple Future Indications
Catalysts About SanBio SanBio is a regenerative medicine company focused on cell therapies for brain diseases such as traumatic brain injury and ischemic stroke. What are the underlying business or industry changes driving this perspective?Shareholder Returns
| 4592 | JP Biotechs | JP Market | |
|---|---|---|---|
| 7D | 1.1% | 2.7% | -1.7% |
| 1Y | -60.4% | -17.7% | 26.7% |
Return vs Industry: 4592 underperformed the JP Biotechs industry which returned -17.7% over the past year.
Return vs Market: 4592 underperformed the JP Market which returned 26.7% over the past year.
Price Volatility
| 4592 volatility | |
|---|---|
| 4592 Average Weekly Movement | 7.4% |
| Biotechs Industry Average Movement | 7.8% |
| Market Average Movement | 3.9% |
| 10% most volatile stocks in JP Market | 8.7% |
| 10% least volatile stocks in JP Market | 1.9% |
Stable Share Price: 4592's share price has been volatile over the past 3 months compared to the JP market.
Volatility Over Time: 4592's weekly volatility (7%) has been stable over the past year, but is still higher than 75% of JP stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2001 | 33 | Keita Mori | www.sanbio.com |
SanBio Company Limited engages in the development, production, and sale of regenerative cell medicines for the central nervous system in Japan and the United States. It develops SB623 that has completed a phase 2 clinical trial to treat traumatic brain injury. The company’s research pipeline products also comprise SB623 for chronic disease, age-related macular degeneration, retinitis pigmentosa, spinal cord injury, Parkinson's disease, Alzheimer's disease, etc.; SB618 to treat peripheral nerve damage; SB308 for muscular dystrophy disease; MSC1 for cancer; and MSC2 for inflammatory disease and optic neuritis.
SanBio Company Limited Fundamentals Summary
| 4592 fundamental statistics | |
|---|---|
| Market cap | JP¥74.00b |
| Earnings (TTM) | -JP¥3.15b |
| Revenue (TTM) | n/a |
Is 4592 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 4592 income statement (TTM) | |
|---|---|
| Revenue | JP¥0 |
| Cost of Revenue | JP¥0 |
| Gross Profit | JP¥0 |
| Other Expenses | JP¥3.15b |
| Earnings | -JP¥3.15b |
Last Reported Earnings
Apr 30, 2026
Next Earnings Date
Sep 17, 2026
| Earnings per share (EPS) | -40.31 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 9.3% |
How did 4592 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/09/14 20:39 |
| End of Day Share Price | 2026/09/14 00:00 |
| Earnings | 2026/04/30 |
| Annual Earnings | 2026/01/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
SanBio Company Limited is covered by 10 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Hidemaru Yamaguchi | Citigroup Inc |
| Stephen Barker | Jefferies LLC |
| Miyabi Yamakita | Jefferies LLC |